The 12th Annual BIO CEO & Investor Conference
An International Biotechnology Investor Conference Featuring Established & Emerging Public Companies
February 8-9, 2010
Waldorf-Astoria
New York City
Add to Outlook The BIO CEO & Investor Conference remains to be the largest investor conference focused on publicly traded biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities.
Our therapeutic workshops feature the latest information on pipeline innovation, and no other investor conference offers as many sessions involving MDs, CSOs, and industry analysts.
BIO’s One-on-One Partnering also provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads.
Registration is now open!
Advisory Commitee:| Alger Boyer | Rodman & Renshaw, LLC |
| Benjamin R. Bowen, Ph.D. | Rodman & Renshaw, LLC |
| Ron Cohen, M.D. | Acorda Therapeutics |
| David Farhadi, M.D. | Fred Alger Management, Inc. |
| Howard Furst, M.D. | Deerfield Management |
| Kelly Lisbakken | Wedbush PacGrow Life Sciences |
| Mark Schoenebaum, M.D. | Deutsche Bank AG |
| Chris Swindle | Wedbush PacGrow Life Sciences |
For more information, please contact BIO CEO customer service:
Email: biopartnering@bio.org
Phone: 866.356.5155, +1.202.962.6666